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Objective: Childhood-onset SLE (cSLE) is a severe lifelong multisystem autoimmune disease. 
Long-term outcome data are limited. Here, we report clinical characteristics and health-
related quality of life (HRQOL) of adults with cSLE. 
 
Methods: Patients underwent a single study visit comprising a structured history and 
physical examination. Disease activity (SLEDAI-2K), damage (SLICC-Damage Index (SDI)) and 
HRQOL (SF-36) were determined. Medical records were retrieved.  
 
Results: In total, 111 cSLE patients were included, median disease duration 20 years, 91% 
female and 72% white. Disease activity was low (median SLEDAI 4), 71% of patients used 
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vast majority of new cSLE-related manifestations developed within 2 years of diagnosis. 
Damage like myocardial infarctions started occurring after 5 years. Most patients (62%) had 
damage, predominantly in the musculoskeletal, neuropsychiatric and renal systems. 
Cerebrovascular accidents, renal transplants, replacement arthroplasties and myocardial 
infarctions, developed at young age (median age 20, 24, 34 and 39 years respectively). 
Multivariate logistic regression showed that damage accrual was associated with disease 
duration (OR=1.15;p<0.001), antiphospholipid-antibody positivity (OR=3.56;p=0.026), and 
hypertension (OR=3.21;p=0.043). Current HCQ-monotherapy was associated with an SDI-
score of 0 (OR=0.16;p=0.009). HRQOL was impaired compared to the Dutch population. 
Presence of damage reduced HRQOL in one domain. High disease activity (SLEDAI≥8) and 
changes in physical appearance strongly reduced HRQOL (4/8 and 7/8 domains).  
 
Conclusions: The majority of adults with cSLE in this large cohort developed significant 
damage at young age and have impaired HRQOL without achieving drug free remission, 
illustrating the great impact of cSLE on future life. 
Systemic lupus erythematosus (SLE) is a lifelong multi-system autoimmune disease, known 
for its highly heterogeneous clinical presentation and waxing-waning disease course. 
Childhood onset SLE (cSLE), defined as SLE with onset < 18 years (1), represents 10-20% of 
all SLE-cases with a mean age at onset of 11-12 years (2, 3). CSLE is a rare disease with an 
incidence ranging from 0.3 – 0.9 per 100.000 person-years, and prevalence of 1.89 to 25.7 
per 100,000 children worldwide (reviewed in (4-6)). Similar to SLE in adults, cSLE is seen 
more often in non-whites and girls (female-male ratio 4-5:1). Disease manifestations differ 
among ethnicities, but clinical outcomes like disease activity and damage tend to be similar 
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Although survival of cSLE patients has greatly improved, morbidity is still high and questions 
from children and parents regarding the future course of the disease are difficult to answer 
(7, 11). Long-term follow-up studies of cSLE patients are limited and often have low patient 
numbers and/or include patients with a relatively short disease duration, and detailed 
evidence regarding development of new organ involvement and damage over time is lacking 
(7, 12-17). Overall, these studies show that the majority of adolescents and young adults 
with cSLE still have active disease, use immunosuppressive drugs and steadily accrue 
damage during their disease (7, 11, 12, 18, 19). Only one North American cohort study of 
both cSLE and adult-onset SLE patients, has included a large number of cSLE patients (n= 90) 
with long disease duration (mean 16.5 years) and compared outcomes of cSLE to adult-
onset SLE (18). In this study, structured telephone interviews were used to collect patient-
reported clinical outcomes, of which only significant renal outcomes could be validated by 
chart review. At the time of study interview, cSLE patients had lower disease activity and 
were more likely to have ever received and currently be treated with corticosteroids and 
disease-modifying anti-rheumatic drugs (DMARDs) when compared to adult-onset SLE 
patients (18). This was also seen in a cohort comparing cSLE, adult-onset SLE and late-onset 
SLE patients with a disease duration of 12 years (19). In the North American cohort of adult-
onset and cSLE patients, cSLE was shown to be an independent risk factor for mortality (11). 
Due to the nature of this cohort study with primarily patient-reported clinical outcomes, 
data regarding development of damage could not be given.  
In children with cSLE, health-related quality of life (HRQOL) has been shown to be impaired 
compared to healthy peers, which was at least partially attributed to disease activity and 
damage (20, 21). There are no data available regarding HRQOL in patients with cSLE after 
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The Childhood-onset SLE in the Netherlands (CHILL-NL) study aims to assess the burden of 
disease of cSLE in the Netherlands. In this article, we describe the clinical characteristics of 
adults with cSLE, focusing on disease course and damage accrual over time in association 
with HRQOL.  
 
Patients and methods 
Patients. All cSLE patients > 18 years who were treated in any Dutch hospital and met the 
ACR-criteria for SLE (22, 23) were eligible for inclusion in the CHILL-NL study. 
Rheumatologists, immunologists, nephrologists, haematologists, and neurologists in all 88 
Dutch hospitals were contacted. There are hardly any private practices in the Netherlands. 
In addition, as SLE is a systemic disease where hospital diagnostics are essential for optimal 
treatment, rheumatologists in private practices in general do not treat SLE patients. 
Therefore these practices were not contacted. All medical specialists in secondary or tertiary 
hospitals  were contacted via e-mail and folders. They were asked to identify patients with 
SLE in their care that were diagnosed prior to their 18th birthday, and ask these patients if 
they were interested in participation in a study on long-term outcome of their disease. The 
study was also promoted in the magazine and on the website of the Dutch SLE patient 
organization (24). Due to the study design, data regarding mortality of cSLE or clinical 
characteristics of deceased patients could not be retrieved reliably; therefore this study only 
reports data from surviving patients. The Research Ethics Board of the Erasmus Medical 
Centre approved the study (MEC-2013-163) and written informed consent was obtained 
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Data collection 
The CHILL-NL study team designed the study with the help of a patient panel (n=5). All 
patients were seen for a single, 1.5-hour study visit in the Erasmus Medical Centre. If 
patients were not able to travel, the study visit was performed at the hospital of the 
patients’ choice. During the study visit, an extensive medical history was taken using 
structured data collection forms and (validated) questionnaires. Data regarding 
demographics, current health, disease activity, damage, disease onset and progression over 
time, current and previous medication use were collected. Physical examination was 
performed, blood and urine were collected, and the patients completed questionnaires 
regarding health-related quality of life (HRQOL), effects of medication use on physical 
appearance, physical health or mental health (yes/no and open area for explanation), 
education and employment, fertility and family planning, fatigue, depression, coping and 
resilience (25-30). For this article, a selection of the data was used as defined in the 
outcomes. Medical information was requested from any hospital where patients had 
received care. Clinical data collected during the study visit was supplemented and verified 
with the retrieved medical history. Only data that could be verified in the medical records 
are reported.  
 
Demographics. Data regarding demographic characteristics such as age, sex, self-reported 
ethnicity and area of residence were collected by structured questionnaires. Categories of 
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Outcomes 
In this article, we focus on disease activity, medication use, disease manifestations over 
time, damage, HRQOL.  
 
Diagnosis, disease manifestations and damage over time. Number of ACR and SLICC criteria 
and any other cSLE-related manifestations at diagnosis were registered (22, 23, 31). 
Definitions of disease manifestations are listed in the legend of Figure 1. Disease duration 
was defined as the years between study visit and date of diagnosis as reported in the 
medical records. Based on findings in previous studies, disease manifestations of cSLE over 
time were recorded according to six predefined time-frames (7, 32, 33): i) never, ii) prior to 
diagnosis, iii) at diagnosis, iv) <2 years since diagnosis, v) 2-5 years since diagnosis and vi) >5 
years since diagnosis. Age at first myocardial infarction, renal transplantation, 
cerebrovascular accident (CVA) and replacement arthroplasty was derived from the medical 
records. Specific disease manifestations such as antibody positivity were recorded as 
positive or negative if this was found in the medical records, and unknown if this was not 
mentioned in the records. Nephrotic syndrome was recorded to be present if clinical 
manifestations (oedema, proteinuria (3-3.5 g/24 hour) and hypoalbuminemia <25 g/L) were 
present , or if the medical records stated a patient to have had nephrotic syndrome. 
Hypertension was recorded to be present when patients had persistent blood pressures 
over 140/90 mmHg or when the medical records stated patients to have hypertension.  
 
Disease activity and medication use. Disease activity was assessed using the SLEDAI-2k (34). 
High disease activity was defined as SLEDAI≥8 (35, 36). Additionally, patients were asked to 
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activity) to 100 (very high disease activity). Medication use was classified as current use, 
previous use and never used. Corticosteroid and hydroxychloroquine (HCQ) were 
considered separately. Non-HCQ DMARDs were defined as azathioprine, ciclosporin, 
cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil, rituximab and 
tacrolimus. All other medication use, including antiepileptic medication, antihypertensive 
drugs including angiotensin-converting-enzyme inhibitors (ACE-I) and angiotensin II receptor 
blockers (ARB) and coumarins was also registered. Patients were asked in an open ended 
question during the study visit if there were any medications that had affected them 
regarding their physical appearance, physical or mental health, and in what way they were 
affected.  
 
Damage. Disease damage was assessed with the SLE International Collaborating Clinics 
(SLICC)/ACR Damage Index (SDI) (37). Presence of damage was defined as SDI score ≥1. If 
damage had a specific temporal component (i.e. cognitive impairment, renal impairment 
present for at least six months), it was recorded if the item was found in two consecutive 
reports from the medical records.  
HRQOL. HRQOL was assessed using the Short-Form-36 (SF-36), which includes 36 questions 
in 8 health domains: Physical Functioning (PF), Social Functioning (SF), Role limitations due 
to Physical problems (RP), Role limitations due to Emotional problems (RE), Mental Health 
(MH), Vitality (VT), Bodily Pain (BP) and General Health Perception (GH)  (25). HRQOL-scores 
of patients were compared to the general population. Effect of disease activity (low (SLEDAI 
≤4), intermediate (SLEDAI 5-7) and high (SLEDAI≥8)) (35),  SLEDAI-items concerning changes 
in physical appearance (ongoing inflammatory rash and/or alopecia) and damage on HRQOL 
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Statistical analysis 
Group comparisons were made using the Mann-Whitney-U (MWU) or the Kruskall-Wallis 
(KW) test where applicable. One sample t-tests were used for comparisons with normative 
data from the Dutch population. Logistic regression analysis was performed to assess 
associations of individual variables and the development of damage. Selection of these 
variables was based on literature (reviewed in (38)). Presence of damage was defined as 
outcome, pre-determined variables were covariates in the model. Variables with an 
individual effect of p<0.1 were used to build the multivariable model, using a hierarchical 
entry method. In the final, most parsimonious model, variables with an association of 
p<0.05 were considered to contribute. To assess goodness of fit, the Hosmer-Lemeshow test 
was used, and residual statistics (Cook’s distance standardized residuals, deviance and 
leverage) were analysed. All analyses were performed using IBM SPSS Statistics v22 (SPSS 




Patient inclusion: Patients were included in the CHILL-NL study from November 2013 until 
April 2016. Eighty-eight secondary and tertiary hospitals were contacted. Doctors from 18 
hospitals confirmed to have adults with cSLE under their care and sent contact information 
of 121 patients to the study team. An additional 15 patients contacted the study team via 
the patient organization. Of these 136 patients, 111 (82%) were seen for a single study visit. 
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the study to those treated at a certain site: at the Erasmus University center, 23 adults with 
cSLE are treated, of which 17 (74%) participated in the CHILL-NL study.   
 
Most study participants (69%) were treated in a tertiary centre (supplementary figure 1). 
Forty percent of patients lived within the vicinity of the Erasmus Medical Centre. Residences 
of the remaining patients were equally distributed over the rest of the country.  
 
Demographics: Median age at study visit was 33 years, with median disease duration of 20 
years (table 1). Year of diagnosis ranged from 1959 to 2013. Patients were divided into 3 
diagnostic eras according to year of diagnosis. The number of patients in each group was 
equally distributed with 67% of patients being diagnosed before 1990. The most common 
ACR criteria at diagnosis were ANA-positivity, immunological features, and arthritis 
(supplementary figure 2). Almost all participants were female (91%). The majority of 
patients were white (72%), 10% were African/Caribbean, 7% Asian, 3% Hispanic, 1% Arabic, 
and 7% had a mixed heritage. Due to the majority of patients being white, ethnicity was 
dichotomized in white and non-white. These groups did not differ regarding age at onset 
and disease duration.  
 
Medication use: The vast majority of patients (68%) still used corticosteroids and/or non-
HCQ DMARDs at study visit (table 1). Regarding corticosteroid-use, 56 of 111 patients (51%) 
used corticosteroids with or without non-HCQ DMARDs. Of all 111 patients, 68% (76/111) 
currently used HCQ, of whom 29% (22/76) used HCQ monotherapy. Sixty-five percent of 
patients used other, non-anti-inflammatory medications, including anti-hypertensive 
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acid (12%), antidepressants (8%) anti-epileptic medication (5%) and/or erythropoietin (5%). 
When asked about the effects of medication use on physical appearance, physical health or 
mental health, the majority of patients reported to have been impacted negatively. The 
largest impact was reported on physical appearance (89%), which was perceived negatively 
by 93% of the patients. They also reported a negative impact on physical health (36%) and 
mental health (28%). Effects on physical appearance (e.g. weight gain) as well as mental 
health (e.g. mood swings) were mostly attributed to prednisone use. Effects on physical 
health (e.g. nausea) were mostly attributed to non-HCQ DMARDs.  
 
Disease activity: Disease activity was relatively low at study visit (median SLEDAI-score 4, 
median VAS 13). Low complement (32%), skin rashes (14%) and proteinuria (13%) were the 
most common SLEDAI items recorded. No difference was found between the SLEDAI-scores 
of patients using corticosteroids and/or non-HCQ DMARDs, patients using HCQ 
monotherapy or patients using no corticosteroids/non-HCQ DMARDs/HCQ (KW p=0.177).  
 
Infections: Almost half of the patients (50/111) had been admitted to the hospital due to 
infections requiring intravenous antibiotic therapy during their disease course, and 48% was 
admitted more than once (table 1).  
  
Disease manifestations and damage over time  
Organ systems which were most frequently involved, were the skin (e.g. malar or discoid 
rash, cutaneous vasculitis), musculoskeletal system (mainly arthritis), haematological system 
(e.g. haemolytic anaemia, leukopenia) and renal system (e.g. lupus nephritis). The vast 
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haematological and renal) developed within 2 years (figure 1). Cardiovascular, pulmonary 
and central nervous system (CNS) manifestations occurred short- as well as long-term. 
However, within two years of diagnosis, pericarditis, pleuritis and epilepsy were the most 
common manifestations within these organ systems, whereas 5 years after disease 
diagnosis damage was most prevalent (myocardial infarction and CVAs). Manifestations of 
peripheral nervous system and gastro-intestinal system were uncommon and mainly 
occurred 5 years after diagnosis. 
 
Disease damage  
In total, 62% percent of the patients had developed damage. Renal, neuropsychiatric and 
musculoskeletal damage were most prevalent (figure 2A). The percentage of patients with 
damage increased over time (figure 2B). Regarding the development of damage of specific 
organ systems per period of disease duration, musculoskeletal (e.g. avascular necrosis, 
deforming/erosive arthritis), neuropsychiatric (mostly cognitive impairment, often 
combined with seizures requiring treatment >6 months) and renal damage (e.g. end-stage 
renal disease) were most prevalent (figure 2C, supplementary table 1).  
 
Notably, after 10-20 years, when cSLE patients are in their early twenties/thirties, significant 
damage had occurred in more than half of the patients (figure 2C, supplementary table 1). 
At a median age of 20 years, seven cSLE patients (5%) had suffered a CVA. Sixteen of 67 
(24%) patients who had renal involvement during their disease, subsequently developed 
damage (supplementary table 2). Of these 16 patients, 38% received a renal transplant 
(median age 24 years). One patient was on renal replacement therapy. Six patients 
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joint replacement. Median age at first joint replacement was 34 years. Five patients had a 
myocardial infarction at a median age of 39 years. Three of them also underwent coronary 
bypass surgery (supplementary table 2). 
 
Factors related to the development of damage 
Logistic regression analysis was performed to assess associations between individual 
variables and development of damage (table 2). Univariate analysis showed longer disease 
duration, and presence of antiphospholipid antibodies (aPL) positivity, infections requiring 
hospitalization (ever), presence of hypertension (ever) and presence of nephrotic syndrome 
(ever) were associated with the presence of damage. Neither gender nor ethnicity had a 
significant association with presence of damage. Current HCQ monotherapy was associated 
with the absence of damage. In the multivariate analysis, disease duration (OR 1.147, 95% CI 
1.077-1.227, p<0.001), hypertension (OR 3.214, 95% CI 1.040-9.932, p=0.033) and aPL-
positivity (OR 3.559, 95% CI 1.161-10.908, p=0.026) were significantly associated with 
presence of damage, and current HCQ monotherapy (OR 0.162, 95% CI 0.042-0.633, 
p=0.009) was again associated with the absence of damage. No differences in number or 
type of organ system involvement or anti-inflammatory medication use were found 
between patients currently using HCQ monotherapy and other patients. 
 
Health-related quality of life 
HRQOL as measured with the SF-36 at study visit was lower in adults with cSLE on 6/8 
domains when compared to the Dutch population (figure 3A). Low disease activity, defined 
as SLEDAI ≤4, positively affected HRQOL (figure 3B). A more detailed evaluation of SLEDAI-










This article is protected by copyright. All rights reserved. 
and/or alopecia (n=25)) revealed a clearly negative impact on HRQOL in 7/8 domains (figure 
3C). Notably, HRQOL in these patients was similar or even lower than in those with high 
disease activity (SLEDAI≥8), even though only 24% of patients with changes in physical 
appearance had high disease activity. An active renal component in the SLEDAI (n=14) did 
not affect HRQOL. No differences were seen in HRQOL between white and non-white 
patients (data not shown). Remarkably, HRQOL was not different in patients with or without 
damage in 7/8 domains, with significantly lower scores only in the Physical Functioning 
domain (figure 3D). Physical functioning domain scores of patients with very long disease 
duration (>30 years) were worse compared to patients with short disease duration (<10 
years). On the other hand, Mental Health domain scores improved over time, with higher 
scores in patients with a long disease duration (data not shown).  
 
Discussion  
This is the first study reporting data regarding disease manifestations over time, damage 
and HRQOL in a large cohort of predominantly white adult patients with cSLE with very long 
disease duration.  
 
Most patients had low disease activity but still used DMARDs and/or corticosteroids 20 
years after diagnosis. More than half of the patients also used medications to treat non-
inflammatory disease or damage-related symptoms. Clearly drug-free remission remains 
difficult to achieve, and current DMARDs are not effective enough to be used without 
corticosteroids in many patients. Indeed, half of patients were still using corticosteroids with 
or without DMARDs, as was reported in other cohorts (cSLE and SLE) with mean disease 
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the development of damage (39). Patients are certainly eager to limit corticosteroid use, as 
almost all patients in the CHILL-NL cohort reported to have negative experiences with 
prednisone regarding their physical appearance and/or mental wellbeing. Although these 
findings may be influenced by  recall bias, they clearly  illustrate the perceived impact of 
corticosteroid use on a patient’s wellbeing, thereby underlining the need for the 
development of new treatment strategies that will be able to further limit or even eliminate 
corticosteroid-use.  
 
Most organ systems became involved within the first two years of diagnosis. Thereafter, 
hardly any new cSLE-related manifestations occurred in organ systems not previously 
affected. This finding was also reported in two cSLE cohorts, but these cohorts only had a 
mean disease duration of four years (32, 40). After 5 years of disease, we showed that the 
nature of disease manifestations shifts to damage such as myocardial infarction, instead of 
primary disease related manifestations like pericarditis or epilepsy. This shift to damage has 
also been observed in adult-onset SLE patients (41-44) and urges for preventative screening 
measures of such (cardiovascular) damage and healthy life-style advice (healthy diet, regular 
exercise, abstinence from smoking). A study looking at (laboratory) markers of 
cardiovascular risk in adolescents with cSLE found that disease duration and signs of renal 
injury (e.g. proteinuria, history of hypertension) were associated with markers of 
cardiovascular risk (45). As we and others show that cardiovascular damage starts occurring 
in patients’ twenties/early thirties, prevention strategies must be considered during 
transition to adult care, especially in patients with renal involvement (12, 18). As infections 
are common in cSLE patients and related to mortality (46, 47), infection prevention by 
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The majority of the patients had developed damage in their mid-twenties and this 
percentage increased with longer disease duration. The musculoskeletal system, kidneys 
and CNS were most frequently affected, as in other cSLE studies albeit describing patients 
with limited disease duration (5-10 years) (13, 15, 16, 19, 50). The only available studies 
reporting damage in patients with mean disease duration of ≥20 years were performed in 
adult-onset SLE (50, 51). Reported frequency and characteristics of damage in these cohorts 
were similar to the results in the CHILL-NL cohort. However, the mean age of diagnosis in 
the adult-onset SLE cohorts was 31 years (50, 51) versus 14 years in our cohort, reflecting 
that most patients with cSLE had started to develop significant damage in their early 
twenties. This is underlined by results from two North-American cSLE-cohorts (mean disease 
duration of 5 years and 16.5 years) that reported myocardial infarction in cSLE patients in 
their early twenties/thirties (12, 18).  
 
Disease duration was the main variable associated with the development of damage in the 
CHILL-NL cohort, next to aPL positivity and hypertension. This is consistently reported in 
many other (c)SLE studies (13, 15, 50-53). Presence of damage did not differ between white 
and non-white patients. Other studies show conflicting results regarding ethnicity and 
development of damage (7, 9, 12). Similar socio-economic status of white and non-white 
patients could possibly explain the lack of association of ethnicity with damage (7-11). Due 
to the low number of men, this study is underpowered to report associations of gender with 
damage. Current HCQ monotherapy was associated with the absence of damage, although 
no information regarding the duration of HCQ monotherapy was registered. Therefore we 
cannot be sure that the group currently on HCQ monotherapy reflects a group of patients 
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anti-inflammatory medication use ever between the patients currently on HCQ 
monotherapy and the other patients.  Longitudinal cohort studies are necessary to clarify 
this issue further. Notably, the association of damage with disease duration also reflects 
past and current treatment modalities. Patients with long disease duration may have 
developed more damage over time due to treatment strategies that are now uncommon 
and more recently diagnosed patients may have had the opportunity to profit from 
improved treatment strategies that lead to less damage. The cross-sectional design of this 
study does not allow dissecting the positive effects of improved treatment modalities from 
the negative effects of disease duration on the development of damage.  
 
This is the first study assessing HRQOL in cSLE patients after reaching adulthood. HRQOL was 
impaired in most domains when compared to the general Dutch population. Other studies 
in children with cSLE and adult-onset SLE patients also showed that patients had an 
impaired HRQOL (21, 54-56) and HRQOL was similar or even lower when compared to 
patients with other chronic illnesses (54-57). A possible explanation for the similar mental 
and emotional health scores in the CHILL-NL cohort might be the development of resilience 
in the patients at a young age to the emotional impact of their disease, as perceived HRQOL 
can be affected by different styles of coping (58). High disease activity (SLEDAI≥8) had a 
significant negative effect, which is supported by other studies (20, 21, 57, 59). Interestingly, 
an even larger negative effect on HRQOL was seen with regard to factors affecting physical 
appearance. Indeed, two other studies showed that changes in physical appearance (e.g. 
obesity, skin involvement) are associated with reduced HRQOL (60, 61). Surprisingly, the 
presence of damage hardly affected HRQOL, with only physical functioning being 
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(21, 52). This discrepancy might be explained by the heterogeneous nature of the developed 
damage that may differ between cohorts, but also to development of adequate coping-
styles in cSLE patients who have learned at an earlier age to adjust their life-style to the 
extent of their damage.  
 
The CHILL-NL study has several strengths. It is a large cohort, and all patients were seen in 
person, providing the possibility to verify disease activity and damage by laboratory analysis 
and physical examination. Medical records were retrieved for all patients, with which all 
reported outcomes were verified. The lack of studies in adults with cSLE show that it is 
challenging to identify patients after transferring to adult care. Even the North-American 
cohort reporting on outcomes of adult cSLE patients has not been designed to specifically 
recruit adults with cSLE (62). This is therefore the largest cohort of cSLE patients with very 
long disease duration that reports on verified disease characteristics as well as HRQOL.  
 
The limitations of the CHILL-NL study must also be addressed. First, the number of patients 
who were not interested in participating in the study and as such were not referred to the 
study team, was unknown. It must be noted that the patients included in this study are not  
a random selection of the total cSLE population in the Netherlands. Patients from both ends 
of the severity spectrum, i.e. patients with severe disease, as well as patients with mild 
disease who do not visit a physician regularly, will be missed in this cross-sectional study 
design.  Patients with high disease activity or severe damage may not have participated in 
the study, as it could be seen as too taxing. To overcome this limitation, we offered to travel 
to the patient if they indicated that travel distance was seen as a barrier. Of the patients 
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due to the cross-sectional nature of the study, deceased patients were missed. As disease 
severity is a risk factor for mortality (11, 50), it is possible that we have a bias towards less 
severe disease in our cohort. This could explain the relatively low renal involvement in the 
CHILL-NL cohort compared to other cSLE studies. Third, data for this study were collected 
retrospectively, and information could have been missed. We chose only to report disease 
characteristics that could be verified with medical records. No data could be collected from 
deceased patients. Consequently, the results from the CHILL-NL study will more likely be an 
underrepresentation than an overrepresentation of the severity of the disease. These 
limitations illustrate the need for longitudinal cohorts that follow cSLE patients even after 
transfer to adult care (12). 
 
In conclusion, the CHILL-NL study shows that cSLE has a major impact on adult life. This is 
the first study to give insight into the development of disease manifestations and damage 
over time in adults with cSLE and their HRQOL. cSLE-related manifestations developed 
mostly within 2 years of diagnosis, with a shift to development of damage 5 years after 
diagnosis. Major medical complications (i.e. renal transplants, CVA, myocardial infarction) 
occurred at young age. These results urge for optimal control of disease activity and 
(cardiovascular) preventative screening measures, starting before the age of thirty, to 
facilitate a better disease prognosis. HRQOL of adults with cSLE is impaired and affected by 
other factors than disease activity or damage alone. By identifying and addressing these 
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Tables 
Table 1. Patient characteristics at study visit 
Characteristics  Number (%) of total (n=111)* 







Age at diagnosis in years, median (range) 14 (4 – 17) 
Age at study visit in years, median (range) 33 (18 – 65) 
Disease duration in years, median (range) 20 (1 – 55) 
Era of diagnosis 








SLEDAI-2K (median, range) 
patients with SLEDAI ≤ 4 
patients with SLEDAI 5 – 7  
patients with SLEDAI ≥ 8 
 









Current corticosteroid/non-HCQ DMARDǂ use 
Corticosteroids + non-HCQ DMARD 
Corticosteroids only 
Non-HCQ DMARD only 
2 non-HCQ DMARDs +/- corticosteroids 
75 (68%) 
40/75  (53%) 
16/75  (21%) 
15/75  (20%) 
 4/75   (5%) 
Current HCQ use 
HCQ + non-HCQ DMARD/corticosteroid 
HCQ monotherapy 
76 (68%) 
54/76  (71%) 
22/76  (29%) 
No HCQ/corticosteroids/ non-HCQ DMARD∆ 14 (13%) 
SDI (median, range) 
SDI ≥ 1 
1 (0 – 8) 
69 (62%) 
Infections requiring I.V. antibiotics (ever) 
Once 




*If number of patients is not given, percentages are of the total cohort (n=111) 
ǂMore information regarding specific DMARD-use can be found in supplementary table 3.  
∆More information regarding these 14 patients can be found in supplementary table 4.  
Abbreviations: HCQ: Hydroxychloroquine; DMARD (Disease Modifying Anti-Rheumatic Drugs): 
azathioprine, ciclosporin, cyclophosphamide, methotrexate, mycophenolate mofetil, tacrolimus, 
rituximab; I.V.: Intravenous; SDI: Systemic Lupus International Collaborating Clinics/American College 
of Rheumatology damage index (37); SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity 
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Table 2: Binary logistic regression analysis of variables associated with damage as outcome measure 
Predictor (n) Univariate Multivariate 
 β OR (95%CI) p β OR (95%CI) p 
Disease duration (111) 0.107 1.113 (1.057-1.171) <0.001 0.139 1.147 (1.077-1.227) <0.001 
Number of ACR criteria at diagnosis (111) 0.036 1.037 (0.786-1.367) 0.798    
Age at diagnosis (111) -0.70 0,933 (0.811-1.072) 0.322    
Use of DMARD/corticosteroids with or without HCQ (75) compared to 
HCQ monotherapy (22) 



















White (80) compared to non-white (31) 0.754 2.215 (0.847-5.329) 0.108*    
Female (101) compared to male (10) -0.964 0.381 (0.077-1.888) 0.237*    
aPL positivity – Negative (44) compared to 




















Renal involvement – Never (44) compared to 
Within 2 years of diagnosis (50)  










   
CNS involvement – Never (78) compared to 
Within 2 years of diagnosis (9) 










   
Nephrotic syndrome (24) compared to no nephrotic syndrome (87) ever 1.738 5.687 (1.578-20.488) 0.008 0.932  0.242† 
Hospitalization (50) compared to no hospitalization due to infection (61) 
ever 
0.505 1.656 (1.098-2.500) 0.016 0.393  0.456† 
Hypertension (71) compared to no hypertension (40) ever 1.522 4.583 (1.792-11.715) 0.001 1.167 3.214 (1.040-9.932) 0.043 
*A cut-off of p<0.100 was set to select the variables for the multivariate logistic regression. As such, these covariates were 
not incorporated in the multivariate model. 
†These covariates were not used for the final multivariate model, as they did not improve the fit of the model.  
Abbreviations: ACR: American College of Rheumatology; β: regression coefficient; DMARD: Disease-Modifying Anti-
Rheumatic Drug; CNS: central nervous system; HCQ: hydroxychloroquine; OR: odds ratio; SDI: Systemic Lupus 
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Figures  
 
Figure 1. First occurrence of disease manifestations over time since diagnosis per organ 
system.  
Definitions of disease manifestations: Skin: malar rash, discoid rash, ulcers, photosensitivity, 
cutaneous vasculitis, other ongoing inflammatory SLE-related rashes; Musculoskeletal: 
arthritis, myositis; Haematological: Haemolytic anaemia, thrombocytopenia, leucopenia, 
lymphopenia, neutropenia, thrombotic thrombocytopenic purpura; Renal: persistent 
proteinuria, lupus nephritis; Cardiovascular: pericarditis, myocarditis, endocarditis, 
myocardial infarction, angina pectoris, cerebrovascular accident, transient ischemic attack, 
arterial thrombosis, venous thrombosis, embolus; Central nervous system: Aseptic 
meningitis, cerebrovascular disease, demyelinating disease, lupus headache, myelopathy, 
chorea, convulsions, acute confusional state, anxiety disorder, mood disorder, psychosis; 
Pulmonary: pleuritic, pneumonia, fibrosis, shrinking lung, pulmonary arterial hypertension, 
interstitial lung disease; Peripheral nervous system: autonomous nervous system disorder, 
mononeuropathy, myasthenia gravis, Guillain-Barré Syndrome; cranial nerve neuropathy, 
plexopathy, polyneuropathy; Gastro-intestinal: peritonitis, pancreatitis, autoimmune 
hepatitis, liver cirrhosis.  
 
Figure 2. Disease damage 
Damage is defined as SDI≥1, the SDI item definitions were used (37). A: Percentage of 
patients with damage with subdivision per organ system. B: Number of patients with and 
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damage relative to the sum of damage scores in all organ systems, displayed per period of 
disease duration.  
Abbreviations: SDI: Systemic Lupus Erythematosus International Collaborating Clinics 
(SLICC)/American College of Rheumatology (ACR) Damage Index (37); IDDM: Insulin 
Dependent Diabetes Mellitus 
 
Figure 3. HRQOL expressed as mean SF36-scores per domain (25)  
These spydergrams show mean scores within each domain of the SF-36, ranging from 0 
(worst) to 100 (best) (63):  
A: SF-36 scores of cSLE patients and the general Dutch population. B: SF-36 scores of 
patients with low (≤4), intermediate (5-7) and high  
SLEDAI-scores (≥8). C: SF-36 scores of patients with SLEDAI-scores pertaining to physical 
appearance (ongoing inflammatory rash and/or alopecia) versus patients without these 
symptoms and patients with SLEDAI≥8. D: SF-36 Scores of patients with damage (SDI≥1) 
versus patients without damage (SDI 0).  
*p<0.05 
Abbreviations: HRQOL: Health Related Quality Of Life; SF36: Short Form-36; cSLE: childhood-
onset Systemic Lupus Erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity 
Index; GH: General Health Perception; PF: Physical Functioning; RP: Role limitations due to 
Physical problems; BP: Bodily Pain; VT: Vitality; MH: Mental Health; RE: Role limitations due 


























This article is protected by copyright. All rights reserved. 
 
 
